SCHEMBL17242573

SCHEMBL17242573

O=c1[nH]c2c(F)cc(Cl)cc2c(=O)n1Cc1ccc(Cl)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRAP1 Q12931 2/20 0.48
KMT2A Q03164 2/20 0.46
LMNA P02545 2/20 0.45
HTT P42858 1/20 0.45
HSP90AA1 P07900 1/20 0.44
HSP90B1 P14625 1/20 0.44
ALDH1A1 P00352 2/20 0.43
KDM4E B2RXH2 2/20 0.43
HPGD P15428 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
DDR1 Q08345 7/20 0.43
POLB P06746 2/20 0.43
MEN1 O00255 1/20 0.43
PKM P14618 1/20 0.43
TLR7 Q9NYK1 3/20 0.42
TP53 P04637 2/20 0.42
MAPT P10636 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
TLR8 Q9NR97 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17242581 0.91 TRAP1 (0.46) TRAP1KMT2AHSP90AA1HSP90B1ALDH1A1
SCHEMBL17242493 0.88 KDM4E (0.58) TRAP1KMT2ALMNAHTTALDH1A1
SCHEMBL17242554 0.82 TRAP1 (0.46) TRAP1KMT2ALMNAHTTHSP90AA1
SCHEMBL17242692 0.79 KDM4E (0.45) TRAP1KMT2AHSP90AA1HSP90B1ALDH1A1
SCHEMBL17241844 0.78 TRAP1 (0.46) TRAP1KMT2ALMNAHTTHSP90B1
SCHEMBL17242605 0.76 KDM4E (0.59) KMT2ALMNAHTTALDH1A1KDM4E
SCHEMBL17242648 0.74 KDM4E (0.60) KMT2ALMNAHTTALDH1A1KDM4E
SCHEMBL17241716 0.74 CA9 (0.59) KMT2ALMNAHTTALDH1A1KDM4E
SCHEMBL17242533 0.74 DDR1 (0.46) TRAP1KMT2AKDM4EDDR1MEN1
SCHEMBL17242582 0.74 KDM4E (0.43) TRAP1KMT2AALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170137387-A1 PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES ORION CORPORATION (FI) 2017-05-18 US disclosed
EP-3140301-A1 PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES Orion Corporation (FI) 2017-03-15 EP disclosed
WO-2015169999-A1 PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES ORION CORPORATION (FI) 2015-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170137387-A1 PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES GABRB1, GABRB3, GABRB2 TRAP1 2858/4885KMT2A 2358/4885LMNA 4675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.